Last reviewed · How we verify
urate oxidase
urate oxidase is a Uricosuric enzyme Small molecule drug developed by Sanofi. It is currently FDA-approved for Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia, Severe hyperuricemia in gout or other conditions. Also known as: rasburicase.
Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine.
Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine. Used for Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia, Severe hyperuricemia in gout or other conditions.
At a glance
| Generic name | urate oxidase |
|---|---|
| Also known as | rasburicase |
| Sponsor | Sanofi |
| Drug class | Uricosuric enzyme |
| Target | Uric acid |
| Modality | Small molecule |
| Therapeutic area | Oncology; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Urate oxidase is a recombinant enzyme that breaks down uric acid by oxidizing it to allantoin, which is approximately 5–10 times more soluble than uric acid. This mechanism rapidly lowers serum and urine uric acid levels, preventing uric acid crystal formation and the complications of tumor lysis syndrome or severe hyperuricemia.
Approved indications
- Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia
- Severe hyperuricemia in gout or other conditions
Common side effects
- Allergic reactions (including anaphylaxis)
- Hemolysis
- Methemoglobinemia
- Infusion-related reactions
Key clinical trials
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients (PHASE2)
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) (PHASE2)
- HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness (PHASE4)
- Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy (NA)
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (PHASE4)
- Mature B-Cell Lymphoma And Leukemia Study III (PHASE2, PHASE3)
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (PHASE3)
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- urate oxidase CI brief — competitive landscape report
- urate oxidase updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about urate oxidase
What is urate oxidase?
How does urate oxidase work?
What is urate oxidase used for?
Who makes urate oxidase?
Is urate oxidase also known as anything else?
What drug class is urate oxidase in?
What development phase is urate oxidase in?
What are the side effects of urate oxidase?
What does urate oxidase target?
Related
- Drug class: All Uricosuric enzyme drugs
- Target: All drugs targeting Uric acid
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Oncology; Rheumatology
- Indication: Drugs for Tumor lysis syndrome prophylaxis and treatment in patients with hematologic malignancies at high risk of hyperuricemia
- Indication: Drugs for Severe hyperuricemia in gout or other conditions
- Also known as: rasburicase